Zovaglutide

What is Zovaglutide?#

Zovaglutide (ZT-002) is a next-generation GLP-1 receptor agonist developed by QL Biopharm (Beijing QL Biopharmaceutical Co., Ltd.) that aims to become the first once-monthly GLP-1 RA for the treatment of obesity. Its innovative dual-fatty acid chain design provides dramatically extended pharmacokinetics compared to existing GLP-1 RAs like semaglutide, which require weekly dosing.

The development of zovaglutide addresses one of the key challenges in chronic obesity treatment: adherence to injection regimens. By reducing dosing from weekly to monthly, zovaglutide could improve treatment persistence and patient convenience while maintaining clinically meaningful weight loss.

Mechanism of Action#

Like other GLP-1 receptor agonists, zovaglutide activates the GLP-1 receptor to:

• Reduce appetite: Acts on hypothalamic GLP-1 receptors to decrease food intake and increase satiety
• Slow gastric emptying: Delays gastric motility, contributing to reduced food intake and postprandial glucose control
• Enhance insulin secretion: Glucose-dependent stimulation of insulin release from pancreatic beta cells
• Suppress glucagon: Reduces hepatic glucose output through glucagon suppression

Dual Fatty Acid Chain Design#

The key innovation in zovaglutide is its dual-fatty acid chain modification, which:

1. Enhances albumin binding: The two fatty acid chains increase binding affinity to serum albumin, creating a circulating depot effect
2. Extends half-life: Pharmacokinetic studies across multiple species showed a 2- to 4-fold longer half-life compared to semaglutide
3. Enables monthly dosing: The extended half-life supports consistent GLP-1 receptor activation over a full month from a single injection
4. Maintains efficacy: Despite the extended interval, zovaglutide achieved competitive weight loss in phase 2 trials

Clinical Development#

Zovaglutide has progressed through phase 1 and phase 2 development:

• Phase 1c (EASD 2024): Dose-ranging study establishing safety, pharmacokinetics, and preliminary efficacy
• Phase 2 (EASD 2025): Randomized, double-blind, placebo-controlled trial in 303 subjects demonstrating 10.6-14.4% weight loss across dose groups at 24 weeks
• Phase 3: Initiated based on positive phase 2 results

Important Considerations#

Zovaglutide is an investigational medication not yet approved by any regulatory authority. Key considerations include:

• The phase 2 trial was 24 weeks in duration; longer-term efficacy and safety data are needed
• Weight loss at 24 weeks may not represent plateau -- further weight loss may occur with longer treatment
• Comparison with approved GLP-1 RAs requires caution due to different trial durations and designs
• As a Chinese-developed drug, the regulatory pathway in Western markets is still being defined

Key Research Findings#

Phase 2 Results of a Monthly Dose Study Evaluating Zovaglutide, a Novel, Extended Half-Life GLP-1 Receptor Agonist (EASD 2025), published in Presented at EASD 2025 (QL Biopharm (Beijing QL Biopharmaceutical), 2025):

• The study showed 160 mg Q4W of 13.8% body weight reduction at 24 weeks vs 2.4% placebo
• The study showed weight loss range across dose groups of 10.6-14.4%

Related Reading#

• Zovaglutide research studies and evidence
• Zovaglutide dosing protocols
• Zovaglutide side effects profile
• MariTide research guide
• MET-097i research guide